Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Mutational analysis of the BRAF gene in human tumor cells.

Ueda M, Toji E, Nunobiki O, Izuma S, Okamoto Y, Torii K, Noda S.

Hum Cell. 2008 May;21(2):13-7. doi: 10.1111/j.1749-0774.2008.00046.x.

PMID:
18397470
2.

Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.

Brzeziańska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E, Lewiński A.

Neuro Endocrinol Lett. 2007 Aug;28(4):351-9.

PMID:
17693984
3.

[BRAF gene mutation in thyroid cancer].

Kopczyńska E, Junik R, Tyrakowski T.

Pol Merkur Lekarski. 2006 Feb;20(116):210-3. Review. Polish.

PMID:
16708643
4.
5.

The RAS-BRAF kinase pathway is not involved in uveal melanoma.

Kiliç E, Brüggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, Luyten GP, de Klein A.

Melanoma Res. 2004 Jun;14(3):203-5.

PMID:
15179189
6.

The T1796A mutation of the BRAF gene is absent in Spitz nevi.

Palmedo G, Hantschke M, Rütten A, Mentzel T, Hügel H, Flaig MJ, Yazdi AS, Sander CA, Kutzner H.

J Cutan Pathol. 2004 Mar;31(3):266-70.

PMID:
14984580
7.

Mutations of the BRAF gene in human cancer.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA.

Nature. 2002 Jun 27;417(6892):949-54. Epub 2002 Jun 9.

PMID:
12068308
8.

Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.

Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G, Tseleni-Balafouta S, Mitsiades CS, Wellmann A, Mitsiades N.

Endocr Relat Cancer. 2009 Jun;16(2):565-72. doi: 10.1677/ERC-08-0101. Epub 2009 Feb 3.

9.

KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay.

Jakubauskas A, Griskevicius L.

Arch Pathol Lab Med. 2010 Apr;134(4):620-4. doi: 10.1043/1543-2165-134.4.620.

PMID:
20367313
10.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

11.

Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).

Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G, Vitale M.

Eur J Endocrinol. 2006 Feb;154(2):341-8.

12.

A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.

Sarkar FH, Valdivieso M, Borders J, Yao KL, Raval MM, Madan SK, Sreepathi P, Shimoyama R, Steiger Z, Visscher DW, et al.

Diagn Mol Pathol. 1995 Dec;4(4):266-73.

PMID:
8634783
13.

Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP.

Dote H, Tsukuda K, Toyooka S, Yano M, Pass HI, Shimizu N.

Oncol Rep. 2004 Feb;11(2):361-3.

PMID:
14719068
14.

Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms.

Miao J, Kusafuka T, Fukuzawa M.

Oncol Rep. 2004 Dec;12(6):1269-72.

PMID:
15547749
15.

High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.

Ney JT, Froehner S, Roesler A, Buettner R, Merkelbach-Bruse S.

Arch Pathol Lab Med. 2012 Sep;136(9):983-92. doi: 10.5858/arpa.2011-0176-OA.

PMID:
22938585
16.

BRAF mutation detection and identification by cycling temperature capillary electrophoresis.

Hinselwood DC, Abrahamsen TW, Ekstrøm PO.

Electrophoresis. 2005 Jun;26(13):2553-61.

PMID:
15948220
17.

BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.

Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, Suzuki A, Konishi I.

Clin Cancer Res. 2005 Sep 1;11(17):6133-8.

18.

Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.

Kirschner M, Helmke B, Starz H, Benner A, Thome M, Deichmann M.

Melanoma Res. 2005 Oct;15(5):427-34.

PMID:
16179870
19.

Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.

Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang CL, Date H.

Anticancer Res. 2011 Dec;31(12):4619-23.

PMID:
22199339
20.

Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.

Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M.

Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26.

PMID:
19474002

Supplemental Content

Support Center